The Rajasthan Royals were celebrating a victory—chasing down a challenging target of 223 runs and winning by six wickets—when the incident occurred. Teammates Yashasvi Jaiswal and Dhruv Jurel were present, witnessing the act that violates not just IPL rules but also Indian law regarding e-cigarettes.

Vaping is strictly prohibited inside IPL stadiums, except in designated smoking zones. The Prohibition of Electronic Cigarettes Act (PECA), enacted in 2019, bans e-cigarette production and use across India. Officials have made it clear that violations can result in imprisonment for up to one year and/or hefty fines of ₹one lakh.

Key developments:

• The BCCI has stated they will seek an explanation from Riyan Parag regarding his actions.
• Officials emphasized that vaping is not allowed within team dressing rooms.
• The visuals captured have drawn significant attention from both fans and cricket authorities.

A BCCI official remarked, “We will be seeking an explanation from Riyan on this issue, as vaping is not allowed.” Depending on his response, further action could follow. This situation puts not just Parag under scrutiny but also sets a concerning precedent for younger players observing their idols.

Earlier this season, Rajasthan Royals manager Romi Bhinder faced fines for using a mobile phone in the dugout—another reminder of how strictly the league enforces its regulations. The focus now shifts to how this incident will impact Riyan Parag’s career and reputation within the team.

This incident raises broader questions about health and safety protocols concerning tobacco products in sports settings. The BCCI’s stringent code of conduct aims to maintain discipline among players, especially given their influence on aspiring cricketers.

As discussions continue online about the implications of this event, everyone waits for clarity on what disciplinary measures might be taken against Parag. The next ruling from the BCCI is expected soon as they assess the situation thoroughly.

The post Vaping: Riyan Parag’s incident sparks controversy in IPL 2026 appeared first on .

The anticipated price of the Fitbit Air is around $99, making it accessible for many looking to enhance their health without breaking the bank. Unlike its competitor Whoop, which requires a monthly subscription for continued access to features, the Fitbit Air promises core health insights upfront—no hidden fees, no ongoing costs. “Unlike Whoop, Fitbit Air is said to skip monthly fees — you pay once and get core health insights upfront,” says one industry observer.

Customization seems to be a significant focus for this new device. With three main colors—Obsidian, Lavender, and Berry—and four different band options including the Performance Loop and Metal Mesh Band, users can tailor their Fitbit Air to fit both their lifestyle and style preferences. The Performance Loop Band will be available in an array of colors like Obsidian and Fog, while the Metal Mesh Band comes in sleek Silver and Warm Gold. Customization is apparently a big focus.

Yet, amid all this excitement, there’s still some uncertainty surrounding the release. It’s still unclear which band will come with the device upon purchase—a detail that many potential buyers are eager to know. Details remain unconfirmed.

The Fitbit Air emerges from Google’s ongoing quest to redefine wearable technology. The company isn’t just competing with Apple Watch anymore; it’s now taking direct aim at Whoop—a move that signals a shift in how fitness tracking devices are perceived and utilized. As more consumers look for ways to integrate health monitoring into their daily lives seamlessly, devices like the Fitbit Air could become essential tools.

The charging cable for the device will be available in Snow white—a small but thoughtful detail that complements its aesthetic appeal. The Active Band will cater to different wrist sizes with small and large options available. This attention to detail highlights how the creators of the Fitbit Air are considering user experience from every angle.

As we approach the launch date, anticipation builds among fitness enthusiasts and casual users alike. With its unique approach to health tracking—free from screens and distractions—the Fitbit Air could change how we engage with our bodies daily. Will it resonate with those who prefer simplicity over complexity?

The world of fitness tracking is about to get more interesting. With its official launch just around the corner, many are watching closely to see how well the Fitbit Air performs against established competitors like Whoop. The future of fitness monitoring could very well hinge on this new device’s success—or failure.

The post Fitbit Air: A New Era in Fitness Tracking appeared first on .

Those affected reported abdominal pain, vomiting, and diarrhoea—a triad of distress that led to their admission in two private hospitals nearby. Thankfully, no casualties have been reported among the group; however, the severity of their conditions necessitated treatment with intravenous fluids. It’s a stark reminder of how quickly comfort food can turn into a source of distress.

Health officials are treating this as a case of suspected food poisoning. Samples of the leftover food have been sent for laboratory testing, with results awaited. Meanwhile, an investigation into food preparation, storage, and hygiene practices is underway—each step crucial in understanding how something so routine could lead to such widespread illness.

Fermented foods like idli and vada require extra care during the sweltering summer months. They’re particularly vulnerable to bacterial contamination if not handled correctly—something health officials have emphasized in light of this incident. Fermentation typically takes around 8-10 hours in cooler months; however, warmer temperatures can accelerate spoilage and increase the risk factors significantly.

As the investigation progresses, it has drawn attention to broader food safety concerns within Bengaluru. The fact that fermented foods have a shorter shelf life in summer—and react faster to temperature and humidity changes—raises questions about current practices in canteens across the city.

This isn’t just an isolated incident; it’s part of a larger conversation about food safety standards in workplace environments. The affected employees worked at a facility in Devanahalli, north Bengaluru—a region where such incidents could easily become more frequent if preventive measures aren’t prioritized.

Still, details remain unconfirmed as health authorities await test results and further insights from their investigation. What’s certain is that this situation has highlighted vulnerabilities in our food systems—vulnerabilities that need addressing before they lead to more serious consequences.

The post Bengaluru Canteen Food Poisoning: 97 Employees Fall Ill appeared first on .

The manager’s reasoning was stark: sick leave could only be granted if the employee was hospitalised for three days with proof. This stringent policy not only disregarded the employee’s immediate health needs but also reflected a broader issue within corporate cultures that often prioritize productivity over well-being. The employee, feeling unsupported, sought medical advice and obtained a doctor’s certificate recommending two days of rest.

With this documentation in hand, he applied for sick leave through the HR portal, which was promptly approved. However, the saga did not end there. The manager, still unconvinced, refused to accept the HR-approved sick leave and demanded to see the prescription. This reaction sparked outrage among Reddit users, who described the manager’s behavior as emblematic of toxic workplace norms that discourage employees from taking necessary time off.

As discussions unfolded online, one Reddit user succinctly captured the sentiment: “Choose health over donkeys. If sick leave is policy-backed and HR-approved, your manager has no business gatekeeping it.” This statement resonated with many, highlighting the need for a shift in workplace attitudes towards sick leave and employee health.

The situation also brings to light the broader context of sick leave policies in India, where the stigma surrounding single-day absences can deter employees from taking time off, even when they are genuinely unwell. This reluctance is compounded by a workplace culture that often views such requests with skepticism, leading to a cycle of stress and burnout.

Moreover, the issue of sick leave is not isolated to individual workplaces. It reflects a larger trend in India, where excessive heat is becoming an increasingly pressing concern. More than 2.4 billion workers globally are exposed to excessive heat, resulting in over 22.85 million occupational injuries each year. In India, projections indicate that the country could lose about 5.8% of working hours by 2030 due to heat stress, a significant increase from 4.3% in 1995.

In 2023 alone, extreme heat cost India an estimated 181 billion potential labour hours, translating into income losses of about Rs 13 lakh crore (approximately $141 billion). Such statistics underscore the urgent need for companies to revisit their sick leave policies and consider the health implications of their workforce.

As the conversation around sick leave continues to evolve, observers suggest that companies must adopt more compassionate and flexible policies that prioritize employee health. The hope is that incidents like this will serve as a catalyst for change, prompting organizations to foster environments where employees feel safe and supported in taking the time they need to recover.

The post Sick leave: The Struggles of in India: A Corporate Employee’s Dilemma appeared first on .

“Together for health. Stand with science,” is the rallying cry as World Health Day 2026 approaches, set to take place on April 7. This year, the theme emphasizes the critical role of scientific collaboration in safeguarding health across the globe.

The campaign, which invites participation through hashtags like #StandWithScience and #WorldHealthDay, is particularly significant as it highlights the One Health approach, recognizing the interconnectedness of human, animal, and environmental health.

On this day, the International One Health Summit will be hosted, bringing together nearly 800 scientific institutions from over 80 countries. This gathering marks a pivotal moment for global health, as experts and stakeholders unite to share knowledge and strategies to tackle pressing health challenges.

In addition to the summit, the inaugural Global Forum of WHO Collaborating Centres will take place from April 7 to 9, further amplifying the message of collaboration and scientific inquiry. This forum is expected to be a melting pot of ideas and innovations aimed at enhancing health outcomes worldwide.

As the world grapples with various health crises, the call to action from the campaign resonates deeply: “We call on governments, scientists, health workers, partners, and the public to stand with science to protect lives, rebuild trust, and secure a healthier future.” This statement underscores the urgent need for collective action in the face of adversity.

The historical context of World Health Day, celebrated annually since 1950, adds weight to this year’s theme. It serves as a reminder of the ongoing efforts to improve health standards and the importance of scientific research in achieving these goals.

As the date approaches, anticipation builds around the discussions and collaborations that will emerge from these significant events. The convergence of nearly 800 institutions signifies a powerful commitment to advancing health through science.

With the world watching, World Health Day 2026 promises to be a landmark occasion, urging individuals and organizations alike to engage in the vital work of health protection and promotion.

Details remain unconfirmed regarding specific outcomes from the summit and forum, but the momentum is palpable as the global community prepares to unite for health.

The post World Health Day 2026: Together for Health, Stand with Science appeared first on .

AIIMS Mangalagiri, a beacon of medical education in Andhra Pradesh, has recently celebrated a significant milestone by conferring degrees on 49 MBBS graduates, five MD/MS postgraduate students, and four Post-Doctoral Certificate Course students. Since its inception in 2018 with an initial intake of just 50 MBBS students, the institution has grown remarkably, now accommodating 748 students with an annual intake of 125.

The growth of AIIMS Mangalagiri is not just in numbers; it reflects a commitment to enhancing healthcare in the region. With a staggering 31 lakh outpatient department (OPD) consultations completed, the hospital currently sees a daily footfall of around 3,500 to 4,000 patients, showcasing its vital role in the community.

In a recent development, the hospital has taken a significant step forward in patient care by installing a Nucleic Acid Amplification Testing (NAAT) system, the first of its kind among all AIIMS in South India. This advanced system, which cost approximately ₹1.73 crore, is designed to detect viral RNA/DNA with high sensitivity, enabling early identification of infections such as HIV, Hepatitis B, and Hepatitis C.

Anupriya Patel, a prominent figure in the government, emphasized the Union government’s commitment to prioritizing the medical sector under Prime Minister Narendra Modi’s leadership. “The Union government under the leadership of Prime Minister Narendra Modi is giving utmost priority to the medical sector,” she stated, highlighting the ongoing efforts to improve healthcare access for the underprivileged.

Ahanthem Singh, a key representative at the event, remarked on the importance of the NAAT system, stating, “The NAAT system enhances safety by significantly reducing the diagnostic window period.” This advancement is expected to greatly benefit patients by providing quicker and more accurate diagnoses.

As AIIMS Mangalagiri continues to evolve, the future looks promising for both its students and the patients they will serve. Observers anticipate that the institution will further enhance its capabilities and expand its services, contributing to the overall improvement of healthcare in the region.

With its ongoing commitment to education and patient care, AIIMS Mangalagiri stands as a testament to the transformative power of healthcare initiatives in India. The community looks forward to witnessing the impact of these new graduates as they step into their roles as healthcare professionals.

The post AIIMS Mangalagiri Celebrates Graduation of New Medical Professionals appeared first on .

Initial reports indicate that the Cicada variant carries approximately 70 to 75 mutations in its spike protein. This extensive mutation profile has raised alarms about its transmissibility and potential resistance to existing vaccines. However, current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This news offers a glimmer of hope amidst the ongoing pandemic.

Common symptoms of the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those associated with previous COVID-19 strains, particularly the Omicron variants. Health experts emphasize that most cases of the Cicada variant appear mild to moderate, resembling flu-like illness, especially among vaccinated individuals. “Most cases remain mild and can be managed at home with rest and hydration,” said a health official.

As of now, the Cicada variant has been detected in over 20 countries, including 25 states in the United States, where it is currently on the rise. This rapid spread has prompted health authorities to actively monitor the situation. Observers note that while the variant is concerning, the symptoms linked to it remain largely consistent with those seen in earlier strains, providing a sense of familiarity in an otherwise unpredictable landscape.

The wider picture

Despite the emergence of the Cicada variant, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health experts recommend that individuals stay up to date with vaccinations and take precautions, particularly in crowded settings where the variant is more likely to spread. The current COVID-19 vaccines may not be as effective against it due to the multiple mutations, but they still play a crucial role in preventing severe outcomes.

As the situation evolves, health authorities continue to gather data and assess the implications of the Cicada variant. While the symptoms may be familiar, the potential for new mutations and changes in transmissibility keeps the public health community on alert. Observers remain hopeful that with continued vigilance and vaccination efforts, the impact of this new variant can be mitigated.

In summary, the Cicada COVID variant is a reminder of the ongoing challenges posed by the pandemic. With its symptoms resembling those of previous strains, it is crucial for individuals to remain informed and proactive in their health measures. As we navigate this new chapter, the collective efforts of health officials, scientists, and the public will be essential in managing the spread of the Cicada variant and protecting communities worldwide.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on .

As the world continues to grapple with the COVID-19 pandemic, a new variant known as Cicada has emerged, first spotted in South Africa in November 2024. This variant, classified as BA.3.2, belongs to the Omicron family and has now made its way to India, prompting health officials to take immediate action.

The Cicada variant is alarming due to its extensive genetic changes, boasting over 70 mutations compared to the original Wuhan strain. Notably, more than 50 of these mutations are found in the spike protein, which is crucial for the virus’s ability to infect human cells.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. While these symptoms are concerning, it is important to note that the Cicada variant has not been confirmed to cause more severe illness than previous variants.

By January 2026, the variant had been detected in 22 countries, with three confirmed cases in the United States, all of whom recovered. The first confirmed case in the U.S. was reported in June 2025, highlighting the variant’s rapid spread.

Dr. Robert Hopkins Jr. commented on the situation, stating, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This uncertainty underscores the need for ongoing surveillance and research.

The CDC has emphasized the importance of monitoring the spread of BA.3.2, as it provides valuable insights into the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations. As the Cicada variant continues to spread, health authorities in India are on high alert, implementing measures to track and contain its transmission.

Details remain unconfirmed regarding the variant’s impact on public health in India, but the situation is evolving rapidly. The emergence of the Cicada variant serves as a reminder that the pandemic is not over and that vigilance is crucial in the fight against COVID-19.

As communities brace for the implications of this new variant, the focus remains on vaccination efforts and public health measures to mitigate the spread of the virus. The coming weeks will be critical in determining how the Cicada variant affects the ongoing pandemic response in India and beyond.

The post Cicada COVID Variant in India: A Growing Concern appeared first on .

The Kerala government has been advocating for the establishment of an All India Institute of Medical Sciences (AIIMS) in the state for several years. Despite submitting multiple proposals, the Union government has yet to approve the project, leaving many residents concerned about the future of healthcare in the region.

In 2025, the Kerala government identified land in Kinalur, Kozhikode, for the proposed AIIMS project, hoping to enhance medical facilities in a state that has long struggled with healthcare access. However, the absence of a timeline for approval from the Centre has left many questioning the commitment to this vital initiative.

Union Minister of State for Health and Family Welfare, Prataprao Jadhav, confirmed that “the proposal for establishing AIIMS in Kerala has not been approved.” This statement underscores the ongoing challenges faced by the state in securing the necessary backing for such a crucial healthcare facility.

The demand for an AIIMS in Kerala has become increasingly politicized, particularly with state Assembly elections on the horizon. Congress MPs Kodikunnil Suresh and Adoor Prakash have voiced their concerns, emphasizing that the lack of an AIIMS is not just a healthcare issue but a significant political one.

Historically, the Kerala government has made numerous attempts to secure approval for an AIIMS, with potential locations identified as early as 2016. In 2019, the Union Health Ministry sought ‘in-principle’ approval from the Finance Ministry, yet progress has stalled since then.

The absence of an AIIMS in Kerala is particularly striking given the state’s pressing healthcare needs. Observers note that the ongoing delays could have serious implications for residents who require specialized medical care.

Details remain unconfirmed regarding the reasons for the delay in approval of the AIIMS proposal. The timeline for its approval or implementation remains unclear, leaving many in the community anxious about their healthcare future.

As the political landscape heats up ahead of the elections, the fate of the AIIMS proposal will likely remain a focal point of discussion among voters and political leaders alike. The Kerala government continues to advocate for the project, hoping to finally bring the much-needed facility to fruition.

The post AIIMS Proposal in Kerala Faces Continued Delays appeared first on .

Sun Pharmaceutical Industries Limited, known for its dedication to advancing patient care, has been making strides in the fields of psoriasis, alopecia areata, and acne. At the recent 2026 AAD Annual Meeting held in Denver, Colorado, the company presented 14 abstracts that underscore its commitment to dermatology and immunology.

Among the key developments highlighted was ILUMYA, a drug focused on treating moderate-to-severe plaque psoriasis and nail psoriasis. This therapy aims to improve the quality of life for patients battling these challenging skin conditions.

Another significant drug, LEQSELVI, is designed for the treatment of severe alopecia areata, a condition that can lead to unpredictable hair loss. The introduction of such therapies reflects Sun Pharma’s ongoing efforts to address unmet medical needs in dermatology.

Additionally, WINLEVI, indicated for acne vulgaris, was also part of the presentations, showcasing its effectiveness in combination therapies. These advancements are crucial as acne remains a prevalent concern among many individuals.

However, not all news was positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about its future in the market. This outcome serves as a reminder of the challenges faced in drug development.

On a brighter note, Nidlegy achieved complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, indicating promising results for this treatment. Observers are particularly keen on the ongoing GLIOSTELLA study, which has completed enrollment in the U.S. for late-line glioblastoma, a significant step in addressing this aggressive cancer.

In light of the recent developments, Sun Pharma is preparing a new submission for Nidlegy following the withdrawal of a prior Marketing Authorization Application in 2025. This proactive approach reflects the company’s resilience and commitment to bringing effective treatments to patients.

Dr. Ahmad Naim, a representative from Sun Pharma, stated, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.” This sentiment resonates with many in the medical community who are eager to see the impact of these therapies on patient care.

As the dust settles from the AAD Annual Meeting, industry observers are closely monitoring the implications of these findings and what they mean for the future of dermatological treatments. The ongoing commitment from companies like Sun Pharma is crucial in the fight against skin diseases, and the next steps in their research will be pivotal.

The post Sun Pharma Advances Dermatology at AAD Annual Meeting appeared first on .